However, high-grade dysplasia, adenocarcinoma, and metastatic cases showed a lower percentage of cases exhibiting strong claudin-7 immunoreactivity (only 50% of cases), with the rest of the cases showing no changing levels [24,27]. This evidence concerns the gene CLDN7 and adenocarcinoma.